Please assess the completion status of the following clinical trial:

Trial Title: Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medical screening.~* Female and male subjects aged 8-16 years and 11 months, with clinical anorexia nervosa and / or reference to the diagnostic criteria of DSM-IV (1) before or at early puberty (Tanner stage 1 or 2) and with a prolonged Catch-Down for at least 18 months (HV ≤ 2 cm / year), with bone age ≤ 12 years in girls and ≤14 years in boys.~* Anorexia nervosa diagnosed at least 1 year before the study~* Growth velocity documented for at least 18 months before inclusion~* As with any child with a severe Catch-Down an assessment of GH secretion must be performed before inclusion (in the context of care) in the trial, which is not conditioned by the GH peak value : GH value of \<20 miu / L will lead to the production of a brain MRI (in the context of care) that have to be normal (normal hypothalamic-pituitary axis and absence of tumor pathology) to allow Inclusion of the patient.~* Normal glucose tolerance~* Stable metabolic state with of weight gain of at least 10% of body weight from the time the body mass index was the lowest in relation to the occurrence of the disease and normal blood electrolytes (no hypokalemia) .~* Subjects whose holders have signed parental consent~* Subjects whose holders of parental authority are affiliated to a social security scheme~* CMU (CMU universal medical coverage).~Exclusion Criteria:~* Subjects in the mid-puberty (Tanner stage 3 or 4) or with menarche.~* Subjects with a chromosomal abnormality or other chronic disease associated chronic requiring long-term treatment.~* Impaired glucose tolerance or diabetes.~* Inability of the patient or the medical team to ensure the progress and monitoring under the protocol.~* Participation in another trial.~* Bradycardia ≤ 50 bpm.~* Children whose holders of parental authority are not beneficiaries of social security~* Contra-indication to SOMATROPINE

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 203 Months
- Healthy Volunteers: f

Study Arms:
- SOMATROPINE* : Norditropine® simplexx® (Type: ACTIVE_COMPARATOR): SOMATROPINE\* : Norditropine® simplexx®
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).